Ansa Biotechnologies
PrivateLast Round
Series B
Oct 1, 2025
Total Funding Raised
$132.59M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ansa Biotechnologies is a biotechnology company that provides enzymatic DNA synthesis services to accelerate biological research and synthetic biology innovation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Usage-Based SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ansa Biotechnologies Comparables
Compare Ansa Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Elegen | 89% | |
| Ribbon Bio | 86% | |
| Camena Bioscience | 85% |
Ansa Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 1, 2025 | ||||
| Series A | Apr 11, 2022 | ||||
| Grant | Apr 15, 2021 | ||||
| Seed | Sep 14, 2020 | ||||
| Pre Seed | Dec 1, 2018 |
Key People
Founding team and executive leadership
Ansa Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Horizons Ventures | Seed, Series A |
| RA Capital Management | Series A |
| Fall Line Capital | Series B |
| Codon Capital | Series A |
| PEAK6 Strategic Capital | Series A |
| Altitude Life Science Ventures | Series A, Series B |
| Carbon Silicon Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 4, 2026
Will present at SynBioBeta 2026 conference in San Jose, CA.
- Mar 31, 2026
Matthias Arenskötter appointed as the new COO.
Recent news
Latest coverage and updates
- signs_new_clientAug 24, 2026
Ansa Biotechnologies, Inc. signed new client Axio BioPharma Inc. on Aug 24th '26.
Ansa Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ansa Biotechnologies's valuation, stock price, and market status.
Is Ansa Biotechnologies a public or private company?
Ansa Biotechnologies is a private company.
What is the current stock price of Ansa Biotechnologies?
Ansa Biotechnologies is a private company with no public stock price. No recent secondary market data is available.
How much is Ansa Biotechnologies worth (valuation)?
Valuation information for Ansa Biotechnologies is not publicly available.
Can I buy Ansa Biotechnologies stock?
Ansa Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ansa Biotechnologies's last funding round?
Ansa Biotechnologies's most recent funding round was Series B on October 1, 2025.
Who are the main investors in Ansa Biotechnologies?
Key investors in Ansa Biotechnologies include Horizons Ventures, Cerberus Ventures, Northpond Ventures, Fifty Years.
Will Ansa Biotechnologies IPO soon?
No public IPO plans have been announced for Ansa Biotechnologies.
How can I track Ansa Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ansa Biotechnologies's secondary market activity and sign up for updates.